Chagas disease is a deadly infection caused by the protozoan parasite *Trypanosoma cruzi*. Afflicting approximately 8 million people in Latin America, Chagas disease is now becoming a serious global health problem proliferating beyond the traditional geographical borders, mainly because of human and vector migration. Because the disease is endemic in low-resource areas, industrial drug development has been lethargic. The chronic form remains incurable, there are no vaccines, and 2 existing drugs for the acute form are toxic and have low efficacy. Here we report the efficacy of a small molecule, VNI, including evidence of its effectiveness against chronic Chagas disease. VNI is a potent experimental inhibitor of *T. cruzi* sterol 14α-demethylase. Nontoxic and highly selective, VNI displays promising pharmacokinetics and administered orally to mice at 25 mg/kg for 30 days cures, with 100% cure rate and 100% survival, the acute and chronic *T. cruzi* infection.

**Keywords.** Chagas disease; *Trypanosoma cruzi*; sterol biosynthesis; sterol 14α-demethylase (CYP51); inhibition; drug discovery; VNI.

Chagas disease is a vector-borne zoonosis. In areas of endemicity, *Trypanosoma cruzi* is mainly transmitted by blood-feeding insects (triatomines; also known as kissing bugs) through their feces and contaminated objects, including crops, food, and drink, with hundreds of different mammalian species forming an inexhaustible reservoir [1]. The area where kissing bug species have been reported spans from the southern parts of South America up to the Great Lakes in the United States [2].

Clinical Chagas disease is classified into acute and chronic phases. The acute phase begins when *T. cruzi* infiltrates the body and starts multiplying within different organs and tissues. The symptoms during this phase can be very mild, nonspecific, and fever like (and often require no medical attention) or severe and sometimes deadly (myocarditis and meningoencephalitis have been reported, with an estimated fatality rate of 0.5% [3]), depending on factors such as the parasite burden and host immunocompetence. The acute phase lasts 4–8 weeks, after which the symptoms cease, and the infection enters the lifelong chronic phase. Intracellular *T. cruzi* amastigotes remain in infected tissues, especially in cardiac and skeletal muscle, but the parasitemia levels become undetectable by microscopy. Clinical symptoms of chronic Chagas disease develop decades later in up to 30% of patients. Therefore, most people remain unaware of their infection and can unwillingly transmit the parasite via blood, tissue, and organ donations and from mother to child. As an example, the estimated number of babies born with congenital Chagas disease each year in the United States, where approximately 300 000 infected persons live [4], ranges from 58 to 582 [5]. The chronic form of Chagas disease is a life-threatening illness that most severely affects the heart and gastrointestinal tract, accounting for nearly 5 times as many disability-adjusted
life-years lost as malaria [2]. In the United States, undiagnosed Chagas disease is responsible for 30,000–45,000 cases of cardiomyopathy [4].

For more than a century since the discovery of T. cruzi, Chagas disease has remained highly neglected. The only 2 drugs used to treat acute-phase disease, benznidazole (since 1960s) and nifurtimox (since 1970s), are impractical because of low efficiency and frequent side effects; neither is approved by the Food and Drug Administration [3]. Treatment of the chronic form of the disease is still mainly limited to the management of symptoms (eg, antiarrhythmic medications, steroids, and pacemakers). Even heart transplantation cannot ensure a cure, because the parasites hidden within other organs will eventually reinfect it. Despite the well-recognized limitations of current therapeutic options and the general acceptance that specific treatment should be offered to all patients [4, 6], Chagas disease still remains outside the commercial interests of pharmaceutical companies, because treatment is considered unprofitable. In academic settings, the development of specific chemotherapeutic approaches was stalled for decades because of the hypothesis that chronic Chagas disease had an autoimmune, rather than an infectious, etiology [7]. Eventually, a clear correlation between T. cruzi and the inflammatory processes was made [8], leading to a consensus that elimination of the parasite from the human body is necessary for cure.

Sterols are essential components of eukaryotic cells. They play key roles in controlling the fluidity and permeability of plasma membranes, as well as in cell development and division. Some eukaryotic phyla (eg, insects) or species (eg, bloodstream forms of Trypanosoma brucei) acquired an ability to scavenge sterols for their membranes from exogenous sources (eg, diet). Others (eg, T. cruzi) must synthesize sterols endogenously. In all cases, sterol deficiency is lethal. Inhibition of sterol biosynthesis is used for treatment of fungal infections. The most efficient clinical antifungals (azoles) target the fungal sterol 14α-demethylase (CYP51), a cytochrome P450 monooxygenase that catalyses oxidative removal of the 14α-methyl group from cyclized sterol precursors [9]. By inhibiting CYP51, azoles block the sterol biosynthetic pathway in the parasites and cause membrane damage, owing to the lack of ergosterol and the accumulation of cytotoxic methylated sterols [10]. Five azole drugs that are currently used for treatment of systemic fungal infections represent modifications of 2 basic inhibitory scaffolds: ketoconazole (I) and fluconazole (II; Figure 1A). Several derivatives of these 2 scaffolds are under development [11]. Some of these antifungals were found to be effective against T. cruzi [7, 12–14], with the 1,2,4-triazole posaconazole (scaffold I; Merck) and ravuconazole (scaffold II; Eisai; Figure 1A) entering clinical trials for Chagas disease [6]. However, ravuconazole has only suppressive rather than curative effects, and it is unable to eradicate T. cruzi in murine and canine models of Chagas disease [13, 15], whereas posaconazole, which resulted in cure in a patient with chronic Chagas disease [16], is too expensive for widespread use in countries where the disease is endemic [4, 16–18]. The cost of posaconazole, estimated to be well over $1000/patient, derives in part from its long (>17 steps for the longest linear sequence) and low-yielding (<1% overall) synthesis [18]. Other drugs with the same mechanism of action, improved safety profile, and lower potential cost are urgently needed [4, 6].

VNI, (R)-N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadi-azol-2-yl)benzamide, represents a novel CYP51 inhibitory scaffold, the first one to come not from antifungal programs but from studying the inhibition of T. cruzi sterol 14α-demethylase activity in the reconstituted reaction in vitro [19]. Later, VNI was structurally characterized in complex with the target enzyme [20, 21]. Structural data suggest that the potency of VNI to inhibit trypanosomal CYP51s (which have only approximately 25% amino acid identity to the fungal CYP51 orthologs) is likely to be enhanced by the hydrogen bond interactions, particularly between the VNI carboxamide fragment and the heme/substrate binding area of the enzyme (Figure 1). Moreover, the inhibitory effect of VNI is highly selective: by acting as a stoichiometric, functionally irreversible inhibitor of protozoan sterol 14α-demethylases, it has a moderate inhibitory effect on fungal (Candida albicans) CYP51 and does not inhibit the human CYP51 ortholog [21]. VNI exhibits no toxicity to mammalian cells [19], and doses of up to 400 mg/kg do not cause signs of acute toxicity in mice in vivo [22]. Unlike posaconazole or fluconazole, this scaffold does not induce T. cruzi CYP51 gene expression and does not require an increase in the dose to maintain its antiparasitic efficiency over time [20], suggesting that it may have a lower propensity to induce resistance.

METHODS

Cellular Infection Assays

The highly invasive trypomastigote clone 20A of the Tulahuen strain of T. cruzi, which was shown to infect >98% of exposed cardiomyocytes [23], was used to evaluate the anti-T. cruzi efficacy of inhibitors in cellular infection assays. T. cruzi trypomastigotes expressing green fluorescent protein GFP were generated as described elsewhere [20, 21]. Trypomastigotes were then used to infect cardiomyocyte monolayers in 96-well tissue culture plates and in 8-well LabTech tissue culture chambers in triplicate at a ratio of 10 parasites per cell. Plates were cultured in Dulbecco’s modified Eagle’s medium (DMEM) free of phenol red and supplemented with 10% fetal bovine serum (FBS) at 37°C in an atmosphere of 5% CO2 for 24 hours. Unbound trypomastigotes were removed by washing with DMEM free of phenol red. Infected monolayers were exposed to several concentrations of the inhibitors VNI, posaconazole, or ravuconazole (range, 1–22 nM), dissolved in...
dimethyl sulfoxide (DMSO)/DMEM free of phenol red in triplicate, and cocultured in DMEM plus 10% FBS for 48 hours to observe parasite multiplication. Seventy-two hours after infection, the cardiomyocyte monolayers were washed with phosphate-buffered saline, and the infection was quantified using a Synergy HT fluorometer (Biotek Instruments) [20]. For fluorescence microscopy of the drug-associated inhibition of *Trypanosoma cruzi* multiplication within cardiomyocytes, infection assays were performed in 8-well LabTech tissue culture chambers in triplicate under the same conditions described above and elsewhere [24]. A total of 72 hours after infection, the monolayers were fixed with 2.5% paraformaldehyde and stained with 4′, 6-diamidino-2-phenylindole, to visualize DNA, and with Alexa fluor 546 phalloidin (Invitrogen), to visualize cardiomyocyte actin myofibrils, which stain red.

**Efficacy Studies in Animal Models of Chagas Disease**

In the model of acute infection [25], female BALB/c mice (Jackson Laboratory; age, 8 weeks; weight, 25 g; 5 mice/group) were injected intraperitoneally with $1 \times 10^5$ cells of bloodstream *T. cruzi*, obtained from the peak of parasitemia in BALB/c mice infected with the Tulahuen strain 20A clone. The Tulahuen strain of *Trypanosoma cruzi* is widely used to evaluate the efficacy of drugs in BALB/c mice [26–29]; the model of *T. cruzi* Tulahuen 20A clone infection in BALB/c mice has been documented elsewhere [30]. The parasites were resuspended
in DMEM to obtain a trypanosome concentration of $1 \times 10^6$ parasites/mL. Each mouse was injected with 0.1 mL of the \textit{T. cruzi} suspension. In these conditions, parasitemia reaches its maximum on day 14 after infection, causing death in 100% of untreated animals. VNI treatment was started 24 hours after infection. A 5% stock solution of VNI in DMSO was dissolved in sterile 5% Arabic gum, and 25 mg/kg was administered twice per day for 30 days by oral gavage. The control mouse group received only the vehicle. Parasitemia was monitored by placing 5 µL of tail blood under a coverslip and counting 100 high-powered fields, as described elsewhere [25]. Animals reaching the peak of parasitemia were euthanized because previous studies showed that animals do not survive for >24 hours after the peak [25]. The day on which mice were euthanized was recorded. The organs (heart, spleen, and liver), skeletal muscle tissue, and blood were analyzed for the presence of parasites by means of real-time polymerase chain reaction (qPCR), as indicated below. Three in vivo independent experiments were performed using the same protocol, and they yielded similar results.

In the model of chronic infection, female BALB/c mice (Jackson Laboratory; age, 8 weeks; weight, 25 g; 9 mice/group) were injected intraperitoneally with a less potent inoculum (50 bloodstream forms) of \textit{T. cruzi} Tulahuen strain 20A clone, which produces a slowly developing parasitemia with a low peak level. Infection is effectively controlled by most infected animals (60%) that survive this initial parasitemic phase. Ninety days after infection, when no circulating parasites were found, VNI (25 mg/kg) or vehicle was orally administered twice daily for 30 days. Between 50 and 70 days after conclusion of VNI treatment, mice in both groups received 6 injections of cyclophosphamide (100 mg/kg) to induce immunosuppression, as described elsewhere [26], to reactivate the infection (Figure 3B). Parasitemia was evaluated as described for the model of acute infection. When parasitemia in the control group (ie, mice receiving only the drug vehicle) reached maximum levels, the blood, tissues, and organs of each mouse from the control and VNI-treated groups were collected to determine the presence of \textit{T. cruzi} by real-time PCR analysis, as described below. Three in vivo independent experiments were performed using the same protocol and provided similar results. Animal studies were conducted under the National Institutes of Health guidelines on the humane use and care of laboratory animals for biomedical research (Guide for the Care and Use of Laboratory Animals. NIH Publication No.85-23. Revised 1985). Protocols were approved by the Meharry Medical College Institutional Animal Care and Use Committee.

**Real-Time PCR for Detection of Tissue and Blood Parasites**

Genomic DNA was purified from the collected organs, tissues, and blood. Parasite genomic DNA was purified from...
epimastigotes. A standard curve in the range of 50 pg to 50 ng for the detection of *T. cruzi* DNA by real-time PCR was developed using the *T. cruzi* 195-bp repeat satellite DNA–specific primers (GenBank accession no. AY520044) that amplified a *T. cruzi* 188-bp sequence, using the primers TCZ1 5′-CGA GCT CTT GCC CAC ACG GGT GCT-3′ and TCZ2 5′-CCT CCA AGC AGC GGA TAG TTC-3′ [27, 31]. The PCR reactions were performed as previously described [32, 33], with minor modifications to detect the presence of parasite DNA in the genomic DNA purified from animal tissues. Samples from each mouse group were tested in triplicate. The mean of mice samples per group and their standard errors are presented.

**Pharmacokinetics**

The pharmacokinetics analysis was based on the VNI-specific absorption maximum (291 nm; \( \sum \text{291} = 36 \text{mM}^{-1} \text{cm}^{-1} \)) and quantification, using 10 μM ketoconazole as an internal standard (\( \sum \text{259} = 6 \text{mM}^{-1} \text{cm}^{-1} \)). VNI was orally administered to a group of 6 BALB/c mice in a single dose (25 mg/kg). Blood samples were collected over time from the mouse tail, using a StatSampler blood collector (Iris Sample Processing, Westwood, MA) as described by the manufacturer, and plasma was collected by centrifugation at 500 g for 5 minutes. VNI was extracted from plasma, using the procedure described by Kraus et al [34]. The samples were centrifuged for 10 minutes at 12,000 g, and the supernatant was dried and then dissolved in a 1:1 ratio of acetonitrile to water. The VNI concentration in plasma was monitored using reverse-phase high-performance liquid chromatography equipped with the dual-wavelength UV 2489 detector (Waters) set at 291 and 259 nm and a Symmetry C18 (3.5 μm) 4.6 × 75-mm column. The injection volume was 100 μL. The mobile phase was 56% 0.01 M potassium phosphate (pH 7.4) and 44% acetonitrile (vol/vol), with an isocratic flow rate of 1.0 mL/minute. VNI and ketoconazole were eluted after 6.5 and 3.9 minutes, respectively. This procedure afforded the detection limit of 0.4 μM (0.2 μg/mL) VNI in 10 μL of mouse plasma.

**Drugs and Analytical Methods**

Synthesis of VNI and its enantiomer as a racemic mixture, followed by chiral separation of R and S enantiomers, was performed as described elsewhere [22]. We recently developed a short, enantioselective, gram-scale synthesis of VNI [35]. Posaconazole and ravuconazole were purchased from Santa Cruz Biotechnology. Reconstitution of CYP51 activity was performed as previously reported [36]. The influence of VNI, ketoconazole, posaconazole, and ravuconazole on the activity of CYP3A4 was compared using a BD Biosciences screening kit, in accordance with the manufacturer instructions; fluorescence was measured using the Molecular Devices Spectramax M5 fluorometer. A standard high-throughput screening thallium assay for detection of human ether-a-go-go–related gene (hERG) activity was performed at the Vanderbilt University High-Throughput Screening Facility to test for the possible influence of VNI on hERG channel (Supplementary Figure S1).

![Figure 3. VNI clears *Trypanosoma cruzi* infection in vivo. A, Acute model of Chagas disease. Mice (5 per group) were intraperitoneally infected with a lethal dose of *T. cruzi* trypomastigotes (1 × 10⁸ organisms), followed by oral treatment, 1 day after infection, with either VNI (25 mg/kg) or with drug vehicle twice per day for 30 days. Inset, Kaplan-Meier survival plot. B, Chronic model of Chagas disease. Mice (9 per group) were intraperitoneally infected with *T. cruzi* blood trypomastigotes (50 organisms) to induce chronicity. Ninety days after infection, oral treatment with VNI (25 mg/kg) or drug vehicle was administered twice daily for 30 days, after which mice were immunsuppressed by 6 injections of cyclophosphamide (CY; arrows) to reactivate infection. Inset, Kaplan-Meier survival plot.](image-url)
RESULTS AND DISCUSSION

Antiparasitic Effect of VNI in *T. cruzi* Amastigotes

*T. cruzi* has a complex life cycle that includes insect and mammalian stages. During the initial, acute phase of infection, the nonreplicative bloodstream trypomastigotes invade different mammalian cell types, where they transform into replicative intracellular amastigotes and multiply within the cytoplasm. Cellular experiments (Figure 2) showed that the potency of VNI in eradicating *T. cruzi* amastigotes from infected cardiomyocytes was higher than the potencies of either posaconazole or ravuconazole (50% maximal effective concentration [EC50], 1.3 nM vs 5 nM). Since the EC50 of VNI for mammalian cells (HL60) is >50 μM, this gives a selectivity index of >50 000, which exceeds the minimal selectivity requirement [37] of at least 2500-fold. A 1-nM concentration represented a 35% maximal effective concentration for VNI and a 15% maximal concentration for posaconazole, whereas 1-nM concentration of ravuconazole displayed no inhibitory effect. A 7.5-nM solution of VNI cleared *T. cruzi* infection in cardiomyocytes, whereas posaconazole and ravuconazole concentrations of >30 nM were required to reach the same effect.

Curative Effect of VNI in the Acute and Chronic Stage of Chagas Disease in the Murine Model

These promising in vitro results encouraged us to start animal treatment using a relatively low oral dose of VNI (25 mg/kg); the reported doses for oral administration of posaconazole in the murine models ranges from 20 to 300 mg/kg [38–41]. In the acute model, the parasitological clearance was 100%, with 100% survival (Figure 3A), and there were no detectable toxic side effects. After VNI treatment, mice did not lose weight and appeared normal. In the chronic model, treatment with VNI started 90 days after infection, lasted for 30 days, and then was followed by 6 rounds of immunosuppressive therapy (Figure 3B). After immunosuppression, all untreated animals had high levels of parasitemia, whereas all VNI-treated mice were free of parasites and survived. In both the acute and chronic models of the disease, qPCR analysis confirmed parasitological clearance: blood and all tested tissues of the VNI treated animals were free of *T. cruzi* (Table 1).

VNI Pharmacokinetics

The curative efficiency of VNI may be enhanced by its promising pharmacokinetic properties (Figure 4). When administered as a single dose by oral gavage (25 mg/kg, which corresponds to the dose used for treatment), VNI reached peak plasma levels of about 40 μM. This exceeded maximal concentrations reported for orally administered posaconazole by 2–9-fold, depending on the experimental details and formulations [38–41], whereas the reported plasma concentrations of ravuconazole did not exceed 4 μM [42–44]. As a starting point, the initial PK of VNI in mice meets perfectly the definition of an ideal target product profile [37]: it is orally available, remains in mouse plasma for >8 hours, reaches the plasma level that exceeds the

---

**Table 1. Results of Real-Time Polymerase Chain Reaction for Detection of *Trypanosoma cruzi* Organs, Tissues, and Blood of Mice**

<table>
<thead>
<tr>
<th>Infection Model, Mouse Group</th>
<th>Heart</th>
<th>Muscle</th>
<th>Liver</th>
<th>Spleen</th>
<th>Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>T. cruzi</em> infected + vehicle</td>
<td>5/5 (12.40 ± 0.13)</td>
<td>5/5 (12.71 ± 0.57)</td>
<td>5/5 (16.26 ± 0.18)</td>
<td>5/5 (12.86 ± 0.20)</td>
<td>5/5 (14.91 ± 0.90)</td>
</tr>
<tr>
<td><em>T. cruzi</em> infected + VNI</td>
<td>0/5 (28.52 ± 0.53)</td>
<td>0/5 (28.82 ± 0.96)</td>
<td>0/5 (28.44 ± 0.71)</td>
<td>0/5 (28.82 ± 0.42)</td>
<td>0/5 (29.52 ± 0.44)</td>
</tr>
<tr>
<td>Uninfected</td>
<td>0/5 (28.63 ± 0.13)</td>
<td>0/5 (28.56 ± 0.20)</td>
<td>0/5 (28.74 ± 0.57)</td>
<td>0/5 (29.36 ± 0.11)</td>
<td>0/5 (28.74 ± 0.10)</td>
</tr>
<tr>
<td><strong>Chronic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>T. cruzi</em> infected + vehicle</td>
<td>9/9 (16.64 ± 0.83)</td>
<td>9/9 (12.90 ± 0.54)</td>
<td>9/9 (15.02 ± 0.27)</td>
<td>9/9 (17.33 ± 1.09)</td>
<td>9/9 (14.59 ± 0.78)</td>
</tr>
<tr>
<td><em>T. cruzi</em> infected + VNI</td>
<td>0/9 (31.98 ± 0.81)</td>
<td>0/9 (28.12 ± 0.84)</td>
<td>0/9 (30.34 ± 1.74)</td>
<td>0/9 (31.62 ± 0.11)</td>
<td>0/9 (30.31 ± 1.62)</td>
</tr>
<tr>
<td>Uninfected</td>
<td>0/9 (28.34 ± 0.66)</td>
<td>0/9 (28.44 ± 0.70)</td>
<td>0/9 (29.90 ± 0.55)</td>
<td>0/9 (29.69 ± 0.61)</td>
<td>0/9 (30.12 ± 0.57)</td>
</tr>
</tbody>
</table>

Data are no. of *T. cruzi*-positive mice/no. in group (mean ± standard error cycle threshold for parasite detection).

---

**Figure 4.** Single-oral-dose profile of the pharmacokinetics of VNI in mouse plasma. VNI was administered by oral gavage at 25 mg/kg. Data represent mean values (±SD) from 6 mice per point. Inset, Log scale for VNI concentration. The arrow shows a possible point of separation between zero- and first-order kinetics.

---

VNI Cures Chagas Disease • JID 2013:208 (1 August) • 509
99% maximal effective concentration for \textit{T. cruzi} within cardiomyocytes by 5000-fold, and has a selectivity index for mammalian(\textit{HL60})/protozoan(\textit{T. cruzi}) cells of >50 000. We surmise that, after proceeding to clinical trials, the VNI oral bioavailability may be further improved by using alternative formulations, such as cyclodextrin solutions, which were proven to increase the bioavailability of posaconazole [40] and other azole compounds [34].

To summarize, VNI cures the acute and chronic forms of Chagas disease in mice, with 100% survival and no observable side effects. Low cost (<$0.10/mg; [35]), oral bioavailability, favorable pharmacokinetics, and low toxicity make this compound an exceptional candidate for clinical trials. The efficacy of VNI provides additional compelling support for efficacious antiparasitic treatment of chronic Chagas disease, further validating CYP51 as a viable drug targeting \textit{T. cruzi}, and it opens a new opportunity for therapeutic cure of patients. Although widespread searches for other new drugs that target \textit{T. cruzi} are surely being pursued, there are millions of patients with this debilitating illness who need immediate therapy, and VNI or a derivative might fulfills this need.

**Supplementary Data**

Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data provided by the author that are published to benefit the reader are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

**Notes**

Acknowledgments. We thank the VICB Synthesis Core (Vanderbilt University), for synthesizing a portion of the VNI used to initiate this study; V. Furtak and C. Taylor, for technical assistance; and M. F. Lima (Meharry Medical College), for reading the manuscript.

Financial support. The work was supported by National Institutes of Health grant GM067871 (GIL, MRW), Vanderbilt Institute of Chemical Biology (VICB) Pilot project grant 2011 (GIL), and in part by GM084333 (INJ), AI080580 and U54 MD007593 (FV), AI083925 (PNN) and AI007281 (CAJ).

Potential conflict of interest. All authors: No reported conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**